Chemomab Therapeutics Ltd DRC Working Capital to Net Assets Ratio
Chemomab Therapeutics Ltd DRC working capital to net assets ratio. Chemomab Therapeutics Ltd DRC (CMMB) has a Working Capital to Net Assets ratio of 96.8% as of June 2026. Working capital of $8.40 Million (current assets of $9.96 Million minus current liabilities of $1.55 Million) is measured against net assets of $8.68 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. Check Chemomab Therapeutics Ltd DRC (CMMB) tangible equity ratio to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Chemomab Therapeutics Ltd DRC (2012–2025)
Working capital to net assets ratio of Chemomab Therapeutics Ltd DRC from 2012 to 2025. This chart shows how Chemomab Therapeutics Ltd DRC's Working Capital to Net Assets ratio has evolved across 12 annual periods from 2012 to 2025. As of June 2026, the ratio stands at 96.8%, reflecting working capital of $8.40 Million against net assets of $8.68 Million USD. See Chemomab Therapeutics Ltd DRC (CMMB) defensive interval to measure how many days the company can operate on defensive assets alone.
Chemomab Therapeutics Ltd DRC Working Capital to Net Assets Ratio by Year (2012–2025)
Chemomab Therapeutics Ltd DRC working capital to net assets ratio by year from 2012 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Chemomab Therapeutics Ltd DRC from 2012 to 2025, covering 12 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see Chemomab Therapeutics Ltd DRC asset portfolio.
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 96.9% | $11.95 Million | $12.33 Million | $13.42 Million | $1.48 Million | ▲ +2.1 pp |
| 2024 | 94.7% | $12.82 Million | $13.54 Million | $16.04 Million | $3.22 Million | ▲ +0.2 pp |
| 2023 | 94.5% | $16.06 Million | $17.00 Million | $20.90 Million | $4.84 Million | ▼ -2.1 pp |
| 2022 | 96.6% | $34.99 Million | $36.22 Million | $41.74 Million | $6.75 Million | ▼ -1.1 pp |
| 2021 | 97.7% | $60.04 Million | $61.47 Million | $62.69 Million | $2.65 Million | ▲ +0.3 pp |
| 2020 | 97.4% | $10.52 Million | $10.80 Million | $11.84 Million | $1.32 Million | ▲ +2.9 pp |
| 2019 | 94.5% | $14.09 Million | $14.91 Million | $18.21 Million | $4.12 Million | ▲ +11.1 pp |
| 2018 | 83.4% | $8.17 Million | $9.80 Million | $10.92 Million | $2.75 Million | ▼ -98.4 pp |
| 2017 | 181.8% | $-1.11 Million | $-609.00K | $1.59 Million | $2.70 Million | ▲ +105.5 pp |
| 2016 | 76.3% | $2.51 Million | $3.29 Million | $4.87 Million | $2.36 Million | ▼ -6.0 pp |
| 2015 | 82.3% | $1.76 Million | $2.14 Million | $3.10 Million | $1.33 Million | ▼ -47.4 pp |
| 2012 | 129.7% | $4.27 Million | $3.29 Million | $9.16 Million | $4.89 Million | — |